Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr S&P Biotech ETF | 9.31% | Reduce −10.9% | 431,215 | $94.89 | $41M | −52,785 | −$2M |
| STXS - Stereotaxis | 8.13% | Hold | 13,680,554 | $2.61 | $36M | — | — |
| CYTK - Cytokinetics | 6.35% | Reduce −0.5% | 398,100 | $70.11 | $28M | −1,900 | −$5M |
| IDYA - Ideaya Biosciences | 4.46% | Reduce −13.6% | 446,341 | $43.88 | $20M | −70,000 | +$1M |
| Merus | 3.89% | Reduce −16.7% | 378,995 | $45.03 | $17M | −75,875 | +$5M |
| RVMD - Revolution Medicines | 3.76% | Hold | 511,894 | $32.23 | $16M | — | — |
| VKTX - Viking Therapeutics | 3.62% | Reduce −21.8% | 194,117 | $82.00 | $16M | −54,100 | +$11M |
| SNDX - Syndax Pharmaceuticals | 3.57% | Reduce −11.2% | 659,574 | $23.80 | $16M | −83,000 | −$349K |
| NDAQ - Ishares Nasdaq Biotech Indx | 3.20% | Hold | 102,500 | $137.22 | $14M | — | — |
| ASND - Ascendis Pharma A/S | 3.18% | Reduce −25.1% | 92,472 | $151.17 | $14M | −31,000 | −$2M |
| XENE - Xenon Pharmaceuticals | 2.68% | Reduce −1.1% | 273,739 | $43.05 | $12M | −3,000 | −$962K |
| DAWNGBX — | 2.51% | Reduce −2.9% | 666,463 | $16.52 | $11M | −20,000 | +$988K |
| Blueprint Medicines | 2.31% | Reduce −3.7% | 106,763 | $94.86 | $10M | −4,100 | −$98K |
| NBIX - Neurocrine Biosciences | 2.25% | Reduce −1.4% | 71,615 | $137.92 | $10M | −1,000 | +$309K |
| Kalvista Pharmaceuticals | 2.18% | Add +34.3% | 806,973 | $11.86 | $10M | +205,941 | +$2M |
| TNDM - Tandem Diabetes Care | 2.08% | Add +17.0% | 258,208 | $35.41 | $9M | +37,500 | +$3M |
| DXCM - Dexcom | 2.07% | Reduce −3.0% | 65,552 | $138.70 | $9M | −2,000 | +$710K |
| KURA - Kura Oncology | 2.00% | Reduce −16.2% | 412,663 | $21.33 | $9M | −80,021 | +$2M |
| ATRC - Atricure | 1.88% | Add +115.9% | 271,029 | $30.42 | $8M | +145,500 | +$4M |
| Morphic | 1.86% | Hold | 231,748 | $35.20 | $8M | — | — |
| AXGN - Axogen | 1.72% | Hold | 935,894 | $8.07 | $8M | — | — |
| BHVN - Biohaven | 1.48% | Reduce −29.7% | 118,730 | $54.69 | $6M | −50,042 | −$730K |
| 2seventy Bio | 1.47% | Reduce −16.8% | 1,204,051 | $5.35 | $6M | −243,414 | +$261K |
| EWTX - Edgewise Therapeutics | 1.27% | Reduce −31.9% | 306,197 | $18.24 | $6M | −143,187 | +$669K |
| ALEC - Alector | 1.25% | Add +49.7% | 912,928 | $6.02 | $5M | +303,023 | +$629K |
| IPSC - Century Therapeutics | 1.24% | Hold | 1,307,407 | $4.18 | $5M | — | — |
| LRMR - Larimar Therapeutics | 1.13% | Add +102.7% | 656,373 | $7.59 | $5M | +332,500 | +$4M |
| Keros Therapeutics | 1.02% | Reduce −8.9% | 67,754 | $66.20 | $4M | −6,607 | +$2M |
| RCUS - Arcus Biosciences | 1.00% | Reduce −0.4% | 231,717 | $18.88 | $4M | −1,000 | −$70K |
| LKFT - Galapagos | 0.95% | Hold | 130,175 | $32.20 | $4M | — | — |
| Perspective Therapeutics | 0.84% | New | 3,103,644 | $1.19 | $4M | +3,103,644 | +$4M |
| BCRX - Biocryst Pharmaceuticals | 0.82% | Hold | 709,500 | $5.08 | $4M | — | — |
| CATBUSD - Astria Therapeutics | 0.72% | Reduce −50.3% | 223,265 | $14.08 | $3M | −225,743 | −$306K |
| Regulus Therapeutics | 0.70% | Reduce −3.6% | 1,070,548 | $2.88 | $3M | −40,501 | +$2M |
| BCYC - Bicycle Therapeutics | 0.69% | Hold | 122,200 | $24.90 | $3M | — | — |
| ARAY - Accuray | 0.69% | Hold | 1,222,358 | $2.47 | $3M | — | — |
| PODD - Insulet | 0.62% | New | 15,900 | $171.40 | $3M | +15,900 | +$3M |
| PRCT - Procept Biorobotics | 0.62% | Reduce −13.1% | 54,995 | $49.42 | $3M | −8,305 | +$65K |
| Mediwound | 0.61% | Reduce −26.7% | 188,753 | $14.25 | $3M | −68,900 | +$69K |
| SPRY - Ars Pharmaceuticals | 0.56% | Reduce −23.1% | 239,194 | $10.22 | $2M | −71,975 | +$739K |
| AQST - Aquestive Therapeutics | 0.48% | New | 500,000 | $4.26 | $2M | +500,000 | +$2M |
| PRQR - Proqr Therapeutics | 0.47% | Reduce −3.7% | 905,582 | $2.29 | $2M | −35,000 | +$211K |
| CMPS - Compass Pathways | 0.46% | Add +26.0% | 243,210 | $8.32 | $2M | +50,210 | +$335K |
| Holding | 0.46% | New | 1,366,308 | $1.48 | $2M | +1,366,308 | +$2M |
| STOK - Stoke Therapeutics | 0.45% | New | 145,000 | $13.50 | $2M | +145,000 | +$2M |
| Sutro Biopharma | 0.43% | Add +18.0% | 334,079 | $5.65 | $2M | +51,000 | +$673K |
| INGN - Inogen | 0.38% | Add +1291.9% | 208,790 | $8.07 | $2M | +193,790 | +$2M |
| Gossamer Bio | 0.38% | Reduce −4.5% | 1,409,262 | $1.18 | $2M | −66,790 | +$316K |
| BWAY - Brainsway | 0.36% | Reduce −3.5% | 297,655 | $5.29 | $2M | −10,816 | −$424K |
| BNTX - Biontech Se | 0.36% | New | 17,000 | $92.25 | $2M | +17,000 | +$2M |
| Immatics | 0.35% | Add +38.1% | 145,000 | $10.51 | $2M | +40,000 | +$418K |
| Neuronetics | 0.34% | Hold | 313,717 | $4.76 | $1M | — | — |
| Adicet Bio | 0.32% | New | 600,000 | $2.35 | $1M | +600,000 | +$1M |
| AUTL - Autolus Therapeutics | 0.31% | Add +13.4% | 216,667 | $6.38 | $1M | +25,597 | +$152K |
| Acelyrin | 0.31% | Reduce −45.4% | 202,587 | $6.75 | $1M | −168,613 | −$1M |
| Iteos Therapeutics | 0.31% | Hold | 98,560 | $13.64 | $1M | — | — |
| MLYS - Mineralys Therapeutics | 0.26% | Add +492.1% | 90,000 | $12.91 | $1M | +74,800 | +$1M |
| Compugen | 0.25% | Add +109.6% | 430,202 | $2.58 | $1M | +225,000 | +$704K |
| IMVT - Immunovant | 0.22% | Reduce −27.8% | 29,416 | $32.31 | $950K | −11,326 | −$766K |
| ACRV - Acrivon Therapeutics | 0.21% | Hold | 131,351 | $7.15 | $939K | — | — |
| APRE - Aprea Therapeutics | 0.21% | New | 137,174 | $6.69 | $918K | +137,174 | +$918K |
| Polypid | 0.19% | New | 185,446 | $4.60 | $853K | +185,446 | +$853K |
| Syros Pharmaceuticals | 0.17% | Reduce −36.8% | 135,850 | $5.35 | $727K | −79,035 | −$947K |
| Adaptimmune Therapeutics | 0.12% | Reduce −2.8% | 341,064 | $1.58 | $539K | −10,000 | +$260K |
| Masimo | 0.10% | Hold | 3,000 | $146.85 | $441K | — | — |
| Nevro | 0.09% | Hold | 28,000 | $14.44 | $404K | — | — |
| Karyopharm Therapeutics | 0.07% | Hold | 192,678 | $1.51 | $291K | — | — |
| Vigil Neuroscience | 0.06% | Hold | 71,815 | $3.41 | $245K | — | — |
| CMPX - Compass Therapeutics | 0.05% | Hold | 116,882 | $1.98 | $231K | — | — |
| Spero Therapeutics | 0.05% | Hold | 125,000 | $1.72 | $215K | — | — |
| ANRO - Alto Neuroscience | 0.03% | New | 10,000 | $15.35 | $154K | +10,000 | +$154K |
Showing top 50 of 71 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Karuna Therapeutics | 3.65% | Exit | 0 | $316.50 | $15M | −48,145 | −$15M |
| Immunogen | 1.38% | Exit | 0 | $29.65 | $6M | −193,661 | −$6M |
| Sage Therapeutics | 1.27% | Exit | 0 | $21.67 | $5M | −245,000 | −$5M |
| Mirati Therapeutics | 1.26% | Exit | 0 | $58.74 | $5M | −89,387 | −$5M |
| AMLX - Amylyx Pharmaceuticals | 0.43% | Exit | 0 | $14.72 | $2M | −122,547 | −$2M |
| Mereo Biopharma Group | 0.43% | Exit | 0 | $2.31 | $2M | −778,813 | −$2M |
| Spruce Biosciences | 0.39% | Exit | 0 | $2.93 | $2M | −548,510 | −$2M |
| Macrogenics | 0.35% | Exit | 0 | $9.62 | $1M | −152,250 | −$1M |
| ARGX - Argen Se | 0.33% | Exit | 0 | $380.56 | $1M | −3,600 | −$1M |
| CGEM - Cullinan Oncology | 0.31% | Exit | 0 | $10.19 | $1M | −127,284 | −$1M |
| ORIC - Oric Pharmaceuticals | 0.16% | Exit | 0 | $9.20 | $670K | −72,797 | −$670K |
| Elevation Oncology | 0.06% | Exit | 0 | $0.5378 | $242K | −450,000 | −$242K |
| Vistagen Therapeutics | 0.05% | Exit | 0 | $5.13 | $215K | −41,886 | −$215K |
| Kinnate Biopharma | 0.03% | Exit | 0 | $2.38 | $119K | −50,000 | −$119K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2